Surprisingly, advances in comprehensive transcriptomic profiling have drastically opened the door to a new field, evoking previous comparisons to the fascinating era of cellular neurophysiology and neuroplasticity research
Online, these consumers often share side-by-side comparisons, not to make claims about outcomes, but to evaluate transparency, ingredient sourcing, and brand reputation
Brand-name GLP-1 medicines dominate If you have insurance, GLP-1s aren't that expensive
Specifically, NAD rejected Willows argument based on physician prescribing practices, stating that an experts conclusory statement or action is of little value and that expert opinions are most reliable when coupled with competent and reliable evidence demonstrating scientific consensus on an issue. NAD also found that studies referenced by Willow concerning the effectiveness of its products for weight loss only involved FDA-approved GLP-1 products and were insufficient to validate claims for compounded alternatives that differ in active pharmaceutical ingredient, formulation or method of administration. Therefore, NAD concluded that Willow did not establish a reasonable basis for its claims and recommended that Willow discontinue or modify its advertising
